news aktuell GmbHnews aktuell GmbH

Dr. Carl June and Dr. Michel Sadelain are being awarded the Broermann Medical Innovation Award 2025

18.9.2025 13:03:31 CEST | news aktuell GmbH | Press Release

Share
  • With prize money of one million euros, it is one of the most highly endowed medical awards in the world
  • Awarded for groundbreaking pioneering work in cancer therapy using CAR-T cells
  • Award Ceremony with Hessian Prime Minister Boris Rhein

Giessen, September 18, 2025. The jury of the Broermann Medical Innovation Award (BMIA) is honoring Dr. Carl June (University of Pennsylvania) and Dr. Michel Sadelain (Columbia University) for their groundbreaking research in the field of CAR-T cell therapy. The Broermann Medical Innovation Award is being presented for the first time this year. With prize money of one million euros, it is among the most highly endowed awards for medical research worldwide.

A Revolution in Cancer Therapy
Dr. Carl June and Dr. Michel Sadelain are recognized for their pioneering roles in the genetic modification of T-cells, which enable these cells to identify, attack, and destroy cancer cells. They use synthetic receptors, so-called chimeric antigen receptors (CARs), which enable T cells to see and kill cancer cells. CAR-T cells achieve remarkable success rates in cancers such as leukemia, lymphomas, and myelomas; for other cancers, this new approach is still in the experimental phase.

Dr. Carl June, the Richard W. Vague Professor in Immunotherapy at the University of Pennsylvania Perelman School of Medicine, says: "I am deeply honored to receive the inaugural Broermann Medical Innovation Award together with my esteemed colleague Michel Sadelain. This award not only recognizes our decades of research but above all the transformative potential of CAR-T cell therapy for cancer patients worldwide."

Dr. Michel Sadelain, Director of the Columbia Initiative in Cell Engineering and Therapy (CICET), says: "Receiving the Broermann Medical Innovation Award is an extraordinary honor for me and a recognition of the revolutionary power of CAR-T cell therapy. Together with Carl June, we have worked to turn the immune system into a precise weapon against cancer. Our work precisely symbolizes what the Broermann Award stands for: medical breakthroughs that fundamentally change patients’ lives. It fills me with profound gratitude to know that our research helps usher in a new era of cancer treatment and create hope for patients who were once considered incurable."

CAR-T cell therapy has achieved remarkable success rates in treating cancers such as leukemia, lymphoma, and myeloma. Through their visionary research, Sadelain and June have ushered in a completely new era in cancer treatment.

Selection process by the renowned jury
The laureates of the Broermann Medical Innovation Award are selected by an outstanding scientific jury consisting of nine senior members of renowned institutes: Prof. Dr. Werner Seeger (Chair of the Broermann Medical Innovation Award), Prof. Dr. Karsten Krüger (Member of the Executive Board of Justus Liebig University Giessen), Prof. Dr. Isabelle Bekeredjian-Ding (Director Center of Infection, Inflammation and Immunity, University of Marburg), Prof. Dr. Britta Siegmund (Vice President of the German Research Foundation), Prof. Dr. Stefan Offermanns (Director of the Max Planck Institute for Heart and Lung Research), Prof. Dr. Otmar Wiestler (President of the Helmholtz Association), Prof. Dr. Dr. Gerd Geißlinger (Director of the Fraunhofer Institute for Clinical Pharmacology), Prof. Dr. Martina Brockmeier (President of the Leibniz Association), and Dr. Jan Liersch (Managing Director of Broermann Holding GmbH). Supported by a group of international reviewers, the committee evaluates all nominations in a multi-stage process that ensures the highest scientific quality and independence. The decision is based on strict selection criteria.

About the laureates
Dr. Carl June was born in Denver, USA, in 1953. He received his MD from Baylor College of Medicine in Houston and his postdoctoral training at the Fred Hutchinson Cancer Research Center in Seattle. Following a research career in the US Navy, June founded the Center for Cellular Immunotherapies (CCI) at the University of Pennsylvania in 1999 and established a leading interdisciplinary research initiative for cellular immunotherapies. In 2012, he received the prestigious Richard W. Vague Professorship.

Dr. Michel Sadelain was born in Paris, France, in 1960 and received his medical degree from the University of Paris in 1984 and his PhD from the University of Alberta, Canada in 1989, before conducting postdoctoral research at the Whitehead Institute for Biomedical Research at the Massachusetts Institute of Technology (MIT). In 1994, he joined Memorial Sloan Kettering Cancer Center in New York. Sadelain now serves as director of the Columbia Initiative in Cell Engineering and Therapy (CICET) center in New York, established in 2024, where he leads innovative cell therapy research.

Both scientists have received numerous scientific prizes for their pioneering contributions to cancer therapy.

About the Broermann Medical Innovation Award
The Broermann Medical Innovation Award was established in 2024 by Dr. Bernard große Broermann, namesake and founder of the Asklepios Kliniken Group. Even during his lifetime, Dr. große Broermann was guided by the vision of creating an innovative healthcare company that delivers real value to people. Under his leadership, Asklepios set new standards in medical innovation, making targeted investments in cutting-edge medical technology and digital solutions, thereby advancing patient care — values that also form the foundation of the Broermann Medical Innovation Award. The award carries forward his vision and continues to highlight the commitment of his foundation beyond his lifetime. With a record prize of one million euros, the award is presented in a formal ceremony at the Hessian State Chancellery in Wiesbaden by the current Hessian Prime Minister, Boris Rhein.

- Picture is available at AP -

 

Press contact:

Broermann Medical Innovation Award

Mirjam Malko

Tel.: +49 (0) 641 / 985-42310

E-Mail: contact@broermann-award.org 

 

Asklepios Kliniken

Konzernbereich Unternehmenskommunikation & Marketing

Tel.: +49 (0) 40 / 18 18-82 66 36

E-Mail: presse@asklepios.com

24-hour press office hotline: +49 (0) 40 / 1818-82 8888


Visit Asklepios on the Internet and Social Media:
www.asklepios.com
www.asklepios.com/gesundheitsmagazin
http://www.youtube.com/asklepioskliniken
de.linkedin.com/company/asklepios
www.instagram.com/asklepioskliniken/
www.facebook.com/asklepioskliniken

Images

Dr. Carl June (Foto: Asklepios)
Dr. Carl June (Foto: Asklepios)
Download
Dr. Michel Sadelain (Foto: Asklepios)
Dr. Michel Sadelain (Foto: Asklepios)
Download

Subscribe to releases from news aktuell GmbH

Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from news aktuell GmbH

DRF Aviation Services launches on October 1, 20261.10.2026 11:28:06 CEST | Press Release

DRF Luftrettung and DRF Maintenance are joining forces: the newly established DRF Aviation Services combines the two companies’ technical expertise built on more than 50 years of experience in helicopter maintenance, modifications and services. As a “one-stop shop”, DRF Aviation Services provides the full range of services from a single source. Helicopter operators benefit from high levels of reliability and innovative capability.

RM Equity Partners (RMEP) completes generational handover – partners take full ownership1.10.2026 09:30:11 CEST | Press Release

Ruggell (LI), 1 October 2026 – RM Equity Partners (RMEP), the international investment firm focused on asset-light digital businesses, today announces the completion of its generational handover. As of 1 October 2026, the management company is fully owned by the three partners Eugen Benedikt Russ, Chris Wittlinger and Nicola Szekely and the wider team, who will make all new investments independently. With this step, the succession within the founding family is concluded: RMEP operates as a fully independent investment firm with no ownership, management or personnel ties to the Russmedia group. RMEP has grown into one of the most active investors in digital marketplaces, software and consumer platforms in Europe: Assets under management of more than €500 million Annual investment capacity of more than €100 million 50+ portfolio investments, with 95% of revenue generated outside Austria Independent evergreen structure – the partners invest their own capital (principal investing, no exter

German pharmacies offering new services: Statistical Yearbook 2026 out now30.9.2026 10:29:22 CEST | Press Release

Berlin / Germany, 30 September 2026 – ABDA – Federal Union of German Associations of Pharmacists has published its Statistical Yearbook “German Pharmacies: Figures, Data, Facts 2026”. The 132-page publication provides a comprehensive overview of the most important facts and statistics of the pharmacy market as well as information on the latest trends in the pharmaceutical and healthcare sectors in Germany and beyond.

MED-EL Launches World’s First Commercially Available Totally Invisible Cochlear Implant29.9.2026 14:00:00 CEST | Press Release

World's first and only commercially available cochlear implant with all components implanted beneath the skin Continuous hearing day and night Hearing performance designed to be the same as established cochlear implant solutions September 29, 2026 – (Innsbruck, Austria): MED-EL, a global leader in hearing implant technology, today announced the launch of TICI UNICO, the world's first and only commercially available totally invisible cochlear implant. Designed for people with severe-to-profound hearing loss, TICI UNICO enables continuous hearing 24 hours a day while remaining completely beneath the skin. It has received CE Mark approval and is being introduced in European markets.

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye